Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Soon BARDA might partner with the company,imo.
$10 is easy by month end,JMO.$20 B market cap is not a big deal for this drug.
This is the "FIRST" drug which could defend Covid-19 in the lungs.Very very ill patients are getting off of ventilators in several days.
$53 Million $ volume !!
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
https://finance.yahoo.com/news/fda-grants-inhaled-ind-rlf-050000708.html?.tsrc=fin-srch
Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung
This might be the breakthrough coronavirus cure we’ve been waiting for
https://bgr.com/2020/08/03/coronavirus-cure-rlf-100-aviptadil-phase-3-trial/
Thanks for posting this.Its huge coming from news and gov official.Word is getting out.
FDA granted EXPANDED ACCESS for RFL-100, does that mean FDA thinks that it could work?.
https://www.prnewswire.com/news-releases/fda-grants-expanded-access-protocol-to-rlf-100-aviptadil-for-respiratory-failure-in-covid-19-currently-in-development-by-neurorx-and-relief-therapeutics-under-fast-track-designation-301101816.html
WOW -BARDA anticipates that the research and development activities supported under the BAA will serve to advance candidate medical countermeasures toward licensure or approval by the FDA.
Submission in response to the BAA occurs in two stages. Stage 1 requires submitting a Quad Chart and White Paper; Stage 2 requires submitting a Full Proposal. Before you submit a White Paper or Full Proposal to the BAA, BARDA strongly recommends that you request a TechWatch meeting to discuss your ideas.
BARDA Broad Agency Announcement (BAA-18-100-SOL-00003)
https://www.phe.gov/about/amcg/BARDA-BAA/Pages/default.aspx
BARDA Broad Agency Announcement BAA-18-100-SOL-00003 Amendment 13
This the text of the pdf research paper released this morning.Look before page numbers.
Rapid Recovery from COVID-19 Respiratory Failure after treatment with Vasoactive Intestinal Peptide
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
No problem.
CONCLUSION - GAME CHANGER
Conclusion:
The rapid clinical improvement seen in these six patients treated with intravenous RLF-100 (Aviptadil), is consistent
with the finding that VIP not only blocks viral replication in the pulmonary epithelium but creates a “bystander effect”
whereby nearby monocytes secrete soluble antiviral agents to further protect ATII cells, blocks cytokine storm, and
improves oxygenation in a lung that is under attack by the SARS-CoV-2 virus. This highly specific role of VIP in the
lung may be key to combating the lethal effects of SARS-CoV-2 infection. A randomized prospective trial is
underway, which will attempt to demonstrate that intravenous RLF-100 improves survival, oxygenation, and clinical
course of Critical COVID-19 with respiratory failure. The independent Data Monitoring Committee of that trial has
conducted the first unblinded look at the study data and identified no safety signals. Moreover, the DMC has
determined that the study is not futile in its objective to identify a statistically significant difference between aviptadil
and placebo in remission from COVID-19 respiratory failure.
The patients reported here were deemed too ill to be randomized in the ongoing phase 2/3 clinical trial of RLF-100 for
treatment of Critical COVID-19. Yet their clinical course, particularly the rapidity with which resolution in COVID
pneumonitis with improvement in oxygenation and radiographic appearance within days is highly atypical for
COVID-19 and suggests that Aviptadil has substantial potential to demonstrate clinical effectiveness in placebocontrolled trials.
I second that.Never seen before, and first of its kind.
THIS IS HUGE - ALL PATIENTS SURVIVED AGE 71
Each of the patients enrolled in this emergency use program was showing active signs of clinical deterioration at the
time of enrollment despite receiving maximal intensive care for COVID-19 related respiratory failure at the Houston
Methodist Hospital. The median age of patients was 71 (Interquartile range [IQR] = 25 years) and there were 3 male
and 3 female patients (Table 1). All patients had known chronic diseases. The most common comorbidities prior to
admission were hypertension (4/6) and chronic kidney disease (4/6). Two patients have known diabetes mellitus, with
Patient 6 being insulin-dependent. Three of the patients had undergone solid organ transplants and were treated with
immunosuppressive agents. Patient 2 received a double lung transplant and was treated for antibody-mediated
rejection (AMR) one month before presentation. Patient 1 was also diagnosed with a non-ST-elevation myocardial
infarction (NSTEMI) during her admission (Table 1). All patients had lab values suggestive of diffuse inflammatory
processes including elevated ferritin (5/6), IL-6 (4/6), lactate dehydrogenase (3/6), and C-reactive protein (3/6).
Prior to enrollment, all patients received anticoagulation as well as dexamethasone without remission from respiratory
failure. Patients were also treated with remdesivir, tocilizumab, and convalescent plasma as available and per
physician discretion. However, supply shortages of these agents were such that only Patient 1 received convalescent
plasma before Aviptadil with no clinical improvement following treatment. Following enrollment and informed
consent, each patient received three 12-hour intravenous infusions of Aviptadil at graduating doses of 50, 100, and
150 pmol/kg/hr.
GAME CHANGER - Below the article is 8 page research paper.Lot of positive info.
Research Paper out today from JohnHopkins,Houston Methodist Hospital and
New York University (NYU) - Langone Medical Center
Rapid Recovery from COVID-19 Respiratory Failure after treatment with Vasoactive Intestinal Peptide
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
$28 MILLION TRADED VOLUME YESTERDAY.
https://www.otcmarkets.com/market-activity/current-market
If it crosses $1, there is no looking back.Its a wonder drug to save lives and money quickly.
The market cap should go beyond atleast $20 Billion to supply the world with RFL-100 after FDA approval.Its showing rapid response in patients in 3 to 4 days,thats a great news.
Helfat: Based on the growing use of rights offerings in large Chapter 11 bankruptcies as a cheaper alternative to secured financing facilities, a means to obtain control over the reorganised company, a mechanism to protect existing equity holders and a vehicle for institutional investors and equity sponsors to continue to realise the ‘upside’ of their capital investments in bankrupt companies, the remainder of 2011 will likely continue to see the use of rights offerings in large Chapter 11 cases.
----------------------------
Thanks for sharing the link.
----------------------------
https://www.financierworldwide.com/rights-offerings-to-exit-bankruptcy#.Xybr6MBlDYV
141. “Reinstated” or “Reinstatement” means, with respect to Claims and Interests, the treatment provided
for in section 1124 of the Bankruptcy Code.
11 U.S. Code §?1124
Except as provided in section 1123(a)(4) of this title, a class of claims or interests is impaired under a plan unless, with respect to each claim or interest of such class, the plan—
(1)leaves unaltered the legal, equitable, and contractual rights to which such claim or interest entitles the holder of such claim or interest; or
(2)notwithstanding any contractual provision or applicable law that entitles the holder of such claim or interest to demand or receive accelerated payment of such claim or interest after the occurrence of a default—
(A)cures any such default that occurred before or after the commencement of the case under this title, other than a default of a kind specified in section 365(b)(2) of this title or of a kind that section 365(b)(2) expressly does not require to be cured;
(B)reinstates the maturity of such claim or interest as such maturity existed before such default;
(C)compensates the holder of such claim or interest for any damages incurred as a result of any reasonable reliance by such holder on such contractual provision or such applicable law;
(D)if such claim or such interest arises from any failure to perform a nonmonetary obligation, other than a default arising from failure to operate a nonresidential real property lease subject to section 365(b)(1)(A), compensates the holder of such claim or such interest (other than the debtor or an insider) for any actual pecuniary loss incurred by such holder as a result of such failure; and
(E)does not otherwise alter the legal, equitable, or contractual rights to which such claim or interest entitles the holder of such claim or interest.
https://www.law.cornell.edu/uscode/text/11/1124
"give-and-take"
Moreover, the Plan, including the Debtor Release, was heavily
negotiated by sophisticated entities that were represented by able counsel and financial advisors.
I believe that the result is a compromise that reflects the give-and-take of a true arm’s-length
negotiation process.
http://www.kccllc.net/windstream/document/1922312200621000000000003
"REINSTATED"
Cancellation of Existing Securities
On the later of the Effective Date and the date on which distributions are made pursuant to the Plan (if not
made on the Effective Date), except as otherwise specifically provided for in the Plan or set forth in the Description
of Restructuring Transactions: (a) the obligations of the Debtors under the Prepetition Credit Agreement, the First
Lien Notes Indenture, the Midwest Notes Indenture, the Second Lien Notes Indenture, the Unsecured Notes
Indentures, and any other certificate, equity security, share, note, bond, indenture, purchase right, option, warrant, or
other instrument or document directly or indirectly evidencing or creating any indebtedness or obligation of or
ownership interest in the Debtors giving rise to any Claim or Interest (except such agreements, certificates, notes, or
other instruments or documents evidencing indebtedness or obligation of or ownership interest in the Debtors that are
reinstated or amended and restated pursuant to the Plan), shall be cancelled solely as to the Debtors, and the
Reorganized Debtors, the DIP Agent, the Agent, the First Lien Notes Indenture Trustees, the Midwest Notes Indenture
Trustee, the Second Lien Notes Indenture Trustees, and the Unsecured Notes Indenture Trustees shall not have any
continuing duties or obligations thereunder and shall be discharged; and (b) the obligations of the Debtors pursuant,
relating, or pertaining to any agreements, indentures, certificates of designation, bylaws or certificate or articles of
incorporation or similar documents governing the shares, certificates, notes, bonds, indentures, purchase rights,
options, or other instruments or documents evidencing or creating any indebtedness or obligation of or ownership
interest in the Debtors (except such agreements, certificates, notes or other instruments evidencing indebtedness or
obligation of or ownership interest in the Debtors that are specifically reinstated, amended and reinstated, or entered
into pursuant to the Plan) shall be released and discharged; except that the applicable indentures and credit agreements
shall continue in effect solely for the purpose of: (i) allowing the applicable agents and indenture trustees to receive
distributions from the Debtors and to make further distributions to the applicable holders of Claims (subject to any
applicable charging liens, including any Second Lien Notes Indenture Trustee Charging Lien and any Unsecured
Notes Indenture Trustee Charging Lien), and allowing such holders to accept distributions, on account of such Claims;
(ii) preserving the applicable agents’ and indenture trustees’ rights to payment of fees and expenses, including any
Second Lien Notes Indenture Trustee Fees and any Unsecured Notes Indenture Trustee Fees, and allowing the
maintenance, exercise, and enforcement of any applicable charging lien, including any Second Lien Notes Indenture
Trustee Charging Lien and any Unsecured Notes Indenture Trustee Charging Lien, for the payment of fees and
expenses, including any Second Lien Notes Indenture Trustee Fees and any Unsecured Notes Indenture Trustee Fees,
and for indemnification as against any money or property distributed to holders; (iii) preserving the right of applicable
agents and indenture trustees to exculpation and indemnification from the Debtors pursuant and subject to the terms
of the applicable credit agreements and indentures; and (iv) preserving the applicable agents’ and indenture trustees’
right to appear and be heard in the Chapter 11 Cases or in any other proceeding in the Bankruptcy Court, including
but not limited to enforcing any obligations owed to it under the Plan or Confirmation Order; provided that nothing in
this Plan shall affect the discharge of Claims pursuant to the Bankruptcy Code, the Confirmation Order, or the Plan,
or result in any liability or expense to the Reorganized Debtors. On the Effective Date, each holder of a certificate or
instrument evidencing a Claim that is discharged by the Plan shall be deemed to have surrendered such certificate or
instrument in accordance with the applicable indenture or agreement that governs the rights of such holder of such
Claim. Such surrendered certificate or instrument shall be deemed cancelled as set forth in, and subject to the
exceptions set forth in, this Article IV.H. On and after the Effective Date, the duties and responsibilities of the
indenture trustees under their respective indenture(s) shall be discharged and released, except (i) to the extent required
to effectuate the Plan including, but not limited to, making distributions under the Plan to the holders of Allowed
Claims under their respective indenture(s) and (ii) with respect to any rights of the First Lien Indenture Trustee , the
Midwest Notes Indenture Trustee, or the Second Lien Indenture Trustees to payment of fees, expenses, and
indemnification obligations as against any money or property distributable to holders of the First Lien Claims under
the First Lien Notes Indenture, to holders of the Midwest Notes under the Midwest Notes Indenture, or to holders of
the Second Lien Claims under the Second Lien Notes Indentures, as applicable, including any rights to priority of
payment and/or to exercise charging liens. After the performance by the applicable agents’ and indenture trustees and
their respective representatives and professionals of any obligations and duties required under or related to the Plan
or the Confirmation Order, the agents and the indenture trustees shall be relieved of and released from any obligations
and duties arising thereunder.
@TonyThomasWIN guy is vacationing and preaching.
Corporate Action - Out of BK
Upon the Effective Date, all actions contemplated by the Plan or as set forth in the Description of
Restructuring Transactions, shall be deemed authorized and approved by the Bankruptcy Court in all respects,
including, as applicable: (a) the issuance of the Reorganized Windstream Equity Interests; (b) the selection of the
directors and officers for Reorganized Windstream and the other Reorganized Debtors; (c) implementation of the
Restructuring Transactions; and (d) all other actions contemplated by the Plan or otherwise deemed necessary or
appropriate by the Debtors, the Reorganized Debtors, or Reorganized Windstream, as the case may be (whether to
occur before, on, or after the Effective Date). Upon the Effective Date, all matters provided for in the Plan involving
the corporate structure of Reorganized Windstream and the other Reorganized Debtors, and any corporate action
required by the Debtors, Reorganized Windstream, or the other Reorganized Debtors in connection with the Plan shall be deemed to have occurred and shall be in effect, without any requirement of further action by the security holders,
directors, or officers of the Debtors, Reorganized Windstream, or the other Reorganized Debtors. On or before the
Effective Date, as applicable, the appropriate officers of the Debtors, Reorganized Windstream, or the Reorganized
Debtors shall be authorized to issue, execute, and deliver the agreements, documents, securities, and instruments
contemplated by the Plan (or necessary to effect the transactions contemplated by the Plan), in the name of and on
behalf of Reorganized Windstream and the other Reorganized Debtors, to the extent not previously authorized by the
Bankruptcy Court. The appropriate officers of the Debtors, Reorganized Windstream, or the Reorganized Debtors
shall be authorized to adopt the execution of any corporate documents to the extent deemed necessary or appropriate.
The authorizations and approvals contemplated by this Article shall be effective notwithstanding any
requirements under non-bankruptcy law
A sale out of BK?.May be.
" present equity interests in Windstream that would exist at emergence"
What does it mean?.
More delays and more good for shareholders,lol.
SHARES DEREGISTERED FOR 401(k) PLAN
https://www.sec.gov/Archives/edgar/data/1282266/000128226620000009/a20200414s-8posfiling2.htm
Thats outright lie.
Proof?.As per the sec i dont see any insider buys since 2018.
https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001282266
Wow you sound like a genius.But i will read company's 8k submitted to sec of the treatment of common shares.
Treatment of Common Stock
As of July 2, 2020, the Company had 43,018,736 shares of common stock issued and outstanding. On the Effective Date or the date on which distributions are made pursuant to the Plan (whichever is later), all outstanding equity interests in the Company will be cancelled and holders of the common stock will not receive a distribution on account of their equity interests.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1282266/000128226620000034/a20200701form8-k.htm
Judge approved plan.As per plan class 9 is getting a big fat zero distribution with shares getting cancelled.
DECN SHOULD ENROLL IN THIS ASAP
https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs
Sharing4 try to contact IR
IR - Its first hand information
Christopher C. King, IRC
Vice President – Investor Relations | Windstream
christopher.c.king@windstream.com
o: 704.319.1025 | m: 410.375.0079
Sharing4 i will help you
Treatment of Common Stock
As of July 2, 2020, the Company had 43,018,736 shares of common stock issued and outstanding. On the Effective Date or the date on which distributions are made pursuant to the Plan (whichever is later), all outstanding equity interests in the Company will be cancelled and holders of the common stock will not receive a distribution on account of their equity interests.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1282266/000128226620000034/a20200701form8-k.htm
THEY ALREADY INFORMED SEC.
Share your opinion ,looks like you did lot of DD.
Treatment of Common Stock
As of July 2, 2020, the Company had 43,018,736 shares of common stock issued and outstanding. On the Effective Date or the date on which distributions are made pursuant to the Plan (whichever is later), all outstanding equity interests in the Company will be cancelled and holders of the common stock will not receive a distribution on account of their equity interests.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1282266/000128226620000034/a20200701form8-k.htm
THEY ALREADY INFORMED SEC.
Due to appeal of the confirmation order, i see the next confirmation would be pushed to atleast 6 months and effective date is atleast 8 months.This will settle down to 1 or 2 cents.IMO.
On the Effective Date or the date on which distributions are made pursuant to the Plan (whichever is later), all outstanding equity interests in the Company will be cancelled and holders of the common stock will not receive a distribution on account of their equity interests.